Seminars in Oncology
Volume 35, Issue 4 , Pages 418-429 , August 2008

Therapy-Related Myeloid Leukemia

  • Lucy A. Godley

      Affiliations

    • Corresponding Author InformationAddress correspondence to Lucy A. Godley, MD, PhD, The University of Chicago MC 2115, 5841 S Maryland Ave, Chicago, IL 60637.
    • ,
  • Richard A. Larson

References 

  1. Godley LA, Larson RA. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In:  Bennett JM editors. The myelodysplastic syndromes: pathobiology and clinical management. New York, NY: Marcel Dekker; 2002;p. 139–176
  2. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104:822–828
  3. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer. 2002;33:331–345
  4. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52
  5. Brunning RD, Matutes E, Flandrin G, et al. Acute myeloid leukaemias and myelodysplastic syndromes, therapy related. In:  Jaffe ES,  Harris NL,  Stein H editor. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001;p. 89–91
  6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  7. Le Beau MM, Espinosa R, Davis EM, et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996;88:1930–1935
  8. Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997;94:6948–6953
  9. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745–1751
  10. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986;105:360–367
  11. Olney HJ, Mitelman F, Johansson B, et al. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:413–423
  12. Coso D, Costello R, Cohen-Valensi R, et al. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Ann Oncol. 1999;10:362–363
  13. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. J Clin Oncol. 2002;20:3878–3884
  14. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005;105:4573–4575
  15. Martin-Salces M, Canales MA, de Paz R, et al. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab. Leuk Res. 2008;32:199–200
  16. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285–4292
  17. Seedhouse C, Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol. 2007;137:513–529
  18. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803–807
  19. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A. 2001;98:11592–11597
  20. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res. 2000;6:4091–4095
  21. Fern L, Pallis M, Ian Carter G, et al. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol. 2004;126:63–71
  22. Bolufer P, Collado M, Barragan E, et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol. 2007;136:590–596
  23. Guillem VM, Collado M, Terol MJ, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia. 2007;21:1413–1422
  24. Sheikhha MH, Tobal K, Liu Yin JA. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002;117:359–365
  25. Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res. 2003;9:3012–3020
  26. Worrillow L, Smith A, Scott K, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet. 2008;45:142–146
  27. Fenske TS, McMahon C, Edwin D, et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 2006;66:5029–5038
  28. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110:719–726
  29. Pedersen-Bjergaard J, Christiansen DH, Desta F, et al. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2006;20:1943–1949
  30. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program. 2004;80–97
  31. Qian Z, Fernald AA, Godley LA, et al. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002;99:14925–14930
  32. Schnittger S, Bacher U, Kern W, et al. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML. Leukemia. 2007;21:183–184
  33. Desta F, Christiansen DH, Andersen MK, et al. Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases. Leukemia. 2006;20:547–548
  34. Christiansen DH, Desta F, Andersen MK, et al. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations. Genes Chromosomes Cancer. 2007;46:517–521
  35. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003;21:1195–1204
  36. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196–205
  37. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25:292–300
  38. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?. Bone Marrow Transplant. 2007;39:59–70
  39. Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol. 2000;71:144–152
  40. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7:81–107
  41. Larson RA, Wernli M, Le Beau MM, et al. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood. 1988;72:1333–1339
  42. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578–2585
  43. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation. J Clin Oncol. 2000;18:963–971
  44. Hale GA, Heslop HE, Bowman LC, et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999;24:735–739
  45. Kroger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2006;37:183–189
  46. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21:2123–2137
  47. Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:395–400
  48. Slovak ML, Bedell V, Popplewell L, et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer. 2002;33:379–394
  49. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120–125
  50. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13:655–664
  51. Kern W, Haferlach T, Schnittger S, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol. 2001;22:2510–2511

 Supported in part by Grants No. CA40046 and CA14599 from the National Cancer Institute.

PII: S0093-7754(08)00122-X

doi: 10.1053/j.seminoncol.2008.04.012

Seminars in Oncology
Volume 35, Issue 4 , Pages 418-429 , August 2008

Article Tools

* Image Usage & Resolution